`
`
`
`
`
`
`Exhibit 1
`
`
`
`
`
`
`
`
`
`Case: 1:17-cv-07903 Document #: 1 Filed: 11/01/17 Page 1 of 6 PageID #:1Case: 1:16-cv-00651 Document #: 72-1 Filed: 12/04/17 Page 2 of 7 PageID #:2395
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE NORTHERN DISTRICT OF ILLINOIS
`EASTERN DIVISION
`
`HOSPIRA, INC.,
`
`
`
`
`
`FRESENIUS KABI USA, LLC
`
`
`
`
`
`
`v.
`
`
`
`
`
`
`
`
`
`
`
`Plaintiff,
`
`Defendant.
`
`
`
`
`
`
`
`
`
`Civil Action No. 17-cv-7903
`
`
`
`
`
`
`Plaintiff Hospira, Inc. (“Hospira”), for its Complaint against Defendant Fresenius Kabi
`
`COMPLAINT
`
`USA, LLC (“Defendant”), hereby alleges as follows:
`
`PARTIES
`
`1.
`
`Hospira is a Delaware corporation with its principal place of business at
`
`275 North Field Drive, Lake Forest, Illinois 60045.
`
`2.
`
`On information and belief, Defendant is a Delaware limited liability
`
`company with its principal place of business at Three Corporate Drive, Lake Zurich, IL 60047.
`
`NATURE OF THE ACTION
`
`3.
`
`This is a civil action for infringement of U.S. Patent No. 9,616,049 (the
`
`“’049 patent”) (Ex. A) (the “Patent-in-suit”).
`
`4.
`
`This action is based upon the Patent Laws of the United States, 35 U.S.C.
`
`§ 1 et seq. and arises out of the Defendant’s filing of Abbreviated New Drug Application
`
`(“ANDA”) No. 208129 seeking approval to market dexmedetomidine hydrochloride products
`
`(“Proposed Fresenius Dexmedetomidine Products”) prior to the expiration of the Patent-in-suit,
`
`
`
`
`
`Case: 1:17-cv-07903 Document #: 1 Filed: 11/01/17 Page 2 of 6 PageID #:2Case: 1:16-cv-00651 Document #: 72-1 Filed: 12/04/17 Page 3 of 7 PageID #:2396
`
`which is assigned to Hospira and listed in the publication entitled Approved Drug Products with
`
`Therapeutic Equivalents (the “Orange Book”) as covering PRECEDEXTM.
`
`JURISDICTION AND VENUE
`
`5.
`
`This action arises under the Patent Laws of the United States, 35 U.S.C. §
`
`1 et seq.
`
`and 1338(a).
`
`6.
`
`This Court has subject matter jurisdiction pursuant to 28 U.S.C. §§ 1331
`
`7.
`
`Defendant is subject to personal jurisdiction in this District by virtue of,
`
`inter alia, its residence and conduct of business in this District. On information and belief,
`
`Defendant’s principal place of business is located in this District at Three Corporate Drive, Lake
`
`Zurich, IL 60047. On information and belief, among Defendant’s operations located in this
`
`District are its Corporate Headquarters, a Science, Production and Technology Center, a
`
`Manufacturing facility, and a Distribution Center. On information and belief, Defendant
`
`develops, formulates, manufactures, markets, and sells drug products throughout the United
`
`States, including Illinois, and Illinois is a likely destination of Defendant’s products. On
`
`information and belief, Defendant has purposely availed itself of the rights and benefits of the
`
`laws of the State of Illinois, and has engaged in substantial and continuous contacts with the
`
`State of Illinois. Defendant has a registered agent for service in the State of Illinois. Moreover,
`
`there is existing litigation between Defendant and Hospira related to patents covering certain
`
`dexmedetomidine hydrochloride products in this District.
`
`8.
`
`Venue is proper in this District pursuant to 28 U.S.C. §§ 1391 and
`
`1400(b).
`
`2
`
`
`
`
`
`Case: 1:17-cv-07903 Document #: 1 Filed: 11/01/17 Page 3 of 6 PageID #:3Case: 1:16-cv-00651 Document #: 72-1 Filed: 12/04/17 Page 4 of 7 PageID #:2397
`
`THE PATENT-IN-SUIT
`
`9.
`
`The ’049 patent, entitled “Dexmedetomidine Premix Formulation,” was
`
`duly and legally issued by the USPTO on April 11, 2017. Hospira is the assignee and owner of
`
`the ’049 patent.
`
`10.
`
`The Patent-in-suit is duly listed in the Orange Book as covering
`
`PRECEDEXTM. The claims of the Patent-in-suit cover various presentations of PRECEDEXTM.
`
`11.
`
`Hospira is the holder of New Drug Application (“NDA”) No. 21-038 for
`
`dexmedetomidine hydrochloride injection, sold in the United States under the trademark
`
`PRECEDEXTM. The United States Food and Drug Administration (“FDA”) originally approved
`
`NDA No. 21-038 on December 17, 1999. On March 13, 2013 and November 14, 2014, the FDA
`
`approved amendments to Hospira’s NDA No. 21-038 for a premix formulation of
`
`PRECEDEXTM.
`
`ACTS GIVING RISE TO THIS ACTION
`
`12.
`
`On October 10, 2017, Hospira received a letter dated October 9, 2017,
`
`from Defendant (“the Notice Letter”), notifying Hospira that Defendant had previously filed
`
`ANDA No. 208129 with the FDA under 21 U.S.C. § 355(j) (i.e., section 505(j) of the Federal
`
`Food, Drug, and Cosmetic Act (“FDCA”)), seeking approval to market the Proposed Fresenius
`
`Dexmedetomidine Products prior to the expiry of the Patent-in-suit.
`
`13.
`
`The stated purpose of the Notice Letter was to notify Hospira that ANDA
`
`No. 208129 included a certification under 21 U.S.C. § 355(j)(2)(a)(vii)(IV) (“Paragraph IV
`
`Certification”) that the claims of the ’049 patent are invalid.
`
`14.
`
`Included in the Notice Letter was a description of the Proposed Fresenius
`
`Dexmedetomidine Products as well as a “detailed statement” of the alleged factual and legal
`
`3
`
`
`
`
`
`Case: 1:17-cv-07903 Document #: 1 Filed: 11/01/17 Page 4 of 6 PageID #:4Case: 1:16-cv-00651 Document #: 72-1 Filed: 12/04/17 Page 5 of 7 PageID #:2398
`
`basis for Defendant’s Paragraph IV Certification. The sole basis set forth in the detailed
`
`statement for Defendant’s Paragraph IV Certification is alleged invalidity.
`
`15.
`
`The Proposed Fresenius Dexmedetomidine Products meet each limitation
`
`of at least one claim of the ’049 patent.
`
`16.
`
`On information and belief, Defendant was aware of Hospira’s patents
`
`related to dexmedetomidine products when it filed ANDA No. 208129. Defendant was further
`
`aware of the ’049 patent when it submitted its updated Paragraph IV Certification.
`
`COUNT I FOR INFRINGEMENT OF PATENT NO. 9,616,049
`
`17.
`
`18.
`
`Paragraphs 1 through 18 are incorporated herein as set forth above.
`
`Defendant submitted ANDA No. 208129 with a Paragraph IV
`
`Certification to the FDA under section 505(j) of the FDCA to obtain approval to engage in the
`
`commercial manufacture, use, sale, offer for sale, and/or importation into the United States of the
`
`Proposed Fresenius Dexmedetomidine Products prior to the expiration of the ’049 patent.
`
`Defendant committed an act of infringement under 35 U.S.C. § 271(e)(2).
`
`19. Moreover, any commercial manufacture, use, sale, offer for sale, and/or
`
`importation into the United States of the Proposed Fresenius Dexmedetomidine Products
`
`described in ANDA No. 208129 would infringe the ’049 patent under 35 U.S.C. § 271(a), (b),
`
`and/or (c). The Notice Letter does not allege non-infringement of any claim of the ’049 patent.
`
`The Proposed Fresenius Dexmedetomidine Products, according to the Notice Letter, meet each
`
`limitation of at least one claim of the ’049 patent.
`
`20.
`
`In addition, Defendant’s actions and conduct, including providing
`
`information and instructions for use of its products in the proposed package insert to accompany
`
`the products, will also encourage direct infringement of the ’049 patent by others.
`
`4
`
`
`
`
`
`Case: 1:17-cv-07903 Document #: 1 Filed: 11/01/17 Page 5 of 6 PageID #:5Case: 1:16-cv-00651 Document #: 72-1 Filed: 12/04/17 Page 6 of 7 PageID #:2399
`
`21.
`
`Defendant was aware of the existence of the Hospira patents related to
`
`dexmedetomidine products prior to the filing of ANDA No. 208129, and provided Hospira with
`
`Defendant’s Paragraph IV Certification knowing it would constitute infringement of the ’049
`
`patent.
`
`22.
`
`Hospira will be irreparably harmed if Defendant is not enjoined from
`
`infringing the ’049 patent.
`
`WHEREFORE, Plaintiff prays for judgment as follows:
`
`PRAYER FOR RELIEF
`
`A.
`
`An order decreeing that the submission to the FDA of ANDA No. 208129
`
`with a Paragraph IV Certification was an act of infringement by Defendant;
`
`B.
`
`An order decreeing that Defendant’s commercial manufacture, use, sale,
`
`offer for sale, and/or importation into the United States of the Proposed Fresenius
`
`Dexmedetomidine Products prior to the expiration of the ’049 patent, including any regulatory
`
`extensions, will infringe, directly and/or indirectly, the ’049 patent;
`
`C.
`
`An order pursuant to 35 U.S.C. 271(e)(4) that the effective date of any
`
`approval of ANDA No. 208129 shall be no earlier than the expiration date of the Patent-in-suit,
`
`including any applicable extensions;
`
`D.
`
`A preliminary and permanent injunction pursuant to 35 U.S.C. § 271(e)(4)
`
`restraining and enjoining Defendant, its officers, agents, attorneys, and employees, and those
`
`acting in privity or concert with it, from engaging in the commercial manufacture, use, offer for
`
`sale, sale, and/or importation into the United States of the Proposed Fresenius Dexmedetomidine
`
`Products described in ANDA No. 208129, or any other ANDA not colorably different from
`
`ANDA No. 208129, until the expiration of the Patent-in-suit, including any applicable
`
`extensions;
`
`5
`
`
`
`
`
`Case: 1:17-cv-07903 Document #: 1 Filed: 11/01/17 Page 6 of 6 PageID #:6Case: 1:16-cv-00651 Document #: 72-1 Filed: 12/04/17 Page 7 of 7 PageID #:2400
`
`E.
`
`A declaration that this case is exceptional and an award of attorneys’ fees
`
`under 35 U.S.C. § 285;
`
`F.
`
`G.
`
`Costs and expenses in this action; and
`
`Such other and further relief as the Court may deem just and proper.
`
`
`Dated: November 1, 2017
`
`
`
`
`
`
`
`
`
`Respectfully Submitted,
`
`HOSPIRA, INC.
`
`By: /s/ Bradford P. Lyerla_____
`
`Bradford P. Lyerla
`Sara T. Horton
`Yusuf Esat
`Chad J Ray
`JENNER & BLOCK LLP
`353 N. Clark Street
`Chicago, IL 60654-3456
`Telephone: 312 222-9350
`Facsimile: 312 527-0484
`blyerla@jenner.com
`shorton@jenner.com
`yesat@jenner.com
`cray@jenner.com
`
`Attorneys for Plaintiff Hospira, Inc.
`
`6
`
`